Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Cytovale

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-movin... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

By LabMedica International staff writers
Posted on 13 Jun 2025

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. More...

In emergency departments (EDs), the absence of reliable and objective early risk assessment tools often leads clinicians to treat a broad range of patients as potentially septic. While this cautious approach is understandable in the high-pressure ED setting, it frequently results in unnecessary and non-beneficial treatments for individuals unlikely to have sepsis. In addition to being a clinical challenge, sepsis also poses a significant financial burden. Hospitals with more than 500 beds may face annual sepsis-related expenditures surpassing USD34 million. A major real-world study now shows that a sepsis diagnostic tool can lower the relative rate of sepsis mortality, reduce hospital stay duration, and improve resource utilization in the ED.

Cytovale’s (San Francisco, CA, USA) IntelliSep stands out as the first and only FDA-cleared diagnostic tool designed to support early detection of sepsis in emergency settings. It uses a standard blood sample and delivers results in approximately eight minutes. This rapid turnaround allows healthcare professionals to assess sepsis risk before traditional clinical symptoms become apparent, enhancing their ability to prioritize care for those in critical need. The integration of this fast diagnostic test with a structured workflow has resulted in what researchers have referred to as a “game-changing model” for healthcare systems across the country. The study tracked over 12,000 patients across a 12-month period at a 900-bed inpatient acute care hospital and Level 1 trauma center, where IntelliSep was used within a nurse-led sepsis triage program aimed at quickly identifying and managing patients at the highest risk.

The findings, detailed in the journal Healthcare, reveal a 39% relative reduction in mortality among sepsis patients, while mortality among non-sepsis patients remained unchanged—highlighting IntelliSep’s role in improving targeted triage. Additionally, the average hospital stay for patients with sepsis was shortened by 0.76 days, signaling benefits for both patient flow and cost management. The research also noted a 40% drop in blood culture use for patients deemed low-risk and an 8% rise in usage among high-risk individuals. These patterns demonstrate IntelliSep’s capacity to enhance diagnostic accuracy and better align testing with patient risk levels.

"This is more than an innovation – it's a paradigm shift in how health systems are managing sepsis," said Dr. Hollis O'Neal, Medical Director of Research at OLOLRMC, the acute care facility which implemented IntelliSep. "For decades, sepsis mortality rates have remained stagnant because we've lacked a fast, reliable way to catch sepsis early. This study proves that with speed, objectivity and accuracy at the point of triage, we can change outcomes before antibiotics are given or ICU beds are needed. That's where real transformation begins."

Related Links:
Cytovale


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.